Antidepressants as monotherapy
|
|
|
|
|
|
|
Amsterdam and Shults 2005 [13] |
34 (BPI = 32, BPII = 2) |
Fluoxetine, olanzapine/fluoxetine combination |
No placebo control |
McElroy et al. 2010 (EMBOLDEN II) [14] |
740 (BPI = 478, BPII = 262) |
Paroxetine |
|
Parker et al. 2006 [16] |
10 BPII |
Escitalopram |
Small sample size |
|
|
|
|
Agosti and Stewart 2007 [21] |
70 BP II |
Imipramine, phenelzine |
No significance demonstrated |
|
|
|
|
Amsterdam and Shults 2008 [17] |
83 BPII |
Venlafaxine |
No placebo control |
|
|
|
|
Amsterdam and Shults 2010 [15] |
148 BPII |
Fluoxetine |
No placebo control |
|
|
|
|
|
Antidepressants with mood stabilizers
|
|
|
|
|
|
|
Schaffer et al. 2006 [27] |
20 |
Citalopram |
Small sample size, no placebo control |
Sachs et al. 2007 [29] |
366 (BPI = 240, BPII = 114) |
Paroxetine, bupropion |
|
Fonseca et al. 2006 [28] |
20 |
Escitalopram |
Small sample size, no placebo control |
Sidor et al. 2011 [32] |
1,034 (Meta- Analysis) |
Fluoxetine, paroxetine, bupropion, imipramine |
|
Tamayo et al. 2009 [46] |
114 |
Olanzapine/fluoxetine combination |
Conducted by Lilly Research Laboratories |
|
|
|
|
Pilhatsch et al. 2010 [41] |
40 |
Paroxetine, amitriptyline |
No placebo control |
|
|
|
|
Perlis et al. 2010 [45] |
410 |
Olanzapine/fluoxetine combination |
Conducted by Lilly Research Laboratories |
|
|
|
|